Physician profile
John D Gross
NPI 1710995543
$4,289.35
in general payments reported to CMS, 2019-2025
28 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $385 · 2021: $630 · 2022: $781 · 2023: $843 · 2024: $606 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $674.56 | 2019-2023 | Iluvien |
| Abbvie INC. | $661.10 | 2022-2025 | |
| Alcon Vision LLC | $502.61 | 2019-2025 | Constellation, Clareon, Argos |
| Astellas Pharma US INC | $351.75 | 2023-2025 | Izervay |
| Genentech USA, INC. | $299.40 | 2022-2023 | Susvimo, Lucentis, Vabysmo |
| Novartis Pharmaceuticals Corporation | $199.93 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $175.56 | 2022-2025 | Xipere, Visudyne |
| Carl Zeiss Meditec, INC. | $173.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $148.23 | 2022-2025 | Eylea Hd |
| Ocular Therapeutix, INC. | $141.94 | 2019-2020 | |
| Genentech, INC. | $139.34 | 2023 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $128.22 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $105.50 | 2020 | |
| Eyepoint US, INC. | $82.39 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $79.57 | 2023-2025 | Iolmaster 700, Cirrus Hd-Oct |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $67.27 | 2025 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $49.84 | 2025 | Xdemvy |
| Allergan, INC. | $46.76 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.67 | 2019-2021 | |
| Oyster Point Pharma, INC. | $44.24 | 2022 | |
| Astellas Pharma Global Development | $33.75 | 2025 | Izervay |
| Omeros Corporation | $24.88 | 2019 | |
| Heidelberg Engineering, INC. | $23.91 | 2020 | |
| Ani Pharmaceuticals, INC. | $22.81 | 2025 | Yutiq |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Research LLC | $18.27 | 2019 | |
| Glaxosmithkline, LLC. | $14.11 | 2022 | |
| Mallinckrodt Hospital Products INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.